Please login to the form below

Not currently logged in
Email:
Password:

uniQure appoints chief executive officer

Matthew Kapusta takes up the lead role in a permanent capacity

uniQure Matthew KapustaBased in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer.

Kapusta had previously served as the gene therapy specialist's interim chief executive since September last year, as well as chief financial officer since January 2015.

Prior to this, Kapusta was senior vice president of medical devices firm AngioDynamics between 2011 and 2014, and has also served as vice president of finance for Smith & Nephew Orthopeadics.

He brings over 10 years of investment banking experience specialising in life sciences, which includes serving as managing director of healthcare investment banking at Collins Stewart.

Kapusta said: “I am honoured and grateful for the trust that the board has placed in me to lead uniQure at this important stage in the company's evolution.

“This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals.

“As we head into 2017, we are fully focused on achieving several important catalysts, including rapidly progressing our hemophilia B programme into late-stage development and advancing our gene therapy candidates for congestive heart failure and Huntington's disease into the clinic.”

10th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...